Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Total Valuation
United Therapeutics has a market cap or net worth of $12.53B. The enterprise value is $14.22B.
Market Cap$12.53B
Enterprise Value$14.22B
Share Statistics
United Therapeutics has 44.91M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44.91M
Owened by Insiders7.08%
Owened by Instutions0.54%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.14%.
Return on Equity (ROE)18.55%
Return on Assets (ROA)16.23%
Return on Invested Capital (ROIC)16.14%
Return on Capital Employed (ROCE)20.78%
Revenue Per Employee$2,204,904.215
Profits Per Employee$915,785.441
Employee Count1,305
Asset Turnover0.39
Inventory Turnover1.96
Valuation Ratios
The current PE Ratio of United Therapeutics is 13.34. United Therapeutics’s PEG ratio is 0.52.
PE Ratio13.34
PS Ratio5.54
PB Ratio2.47
Price to Fair Value2.47
Price to FCF14.76
Price to Operating Cash Flow12.02
PEG Ratio0.52
Income Statement
In the last 12 months, United Therapeutics had revenue of $2.88B and earned $1.20B in profits. Earnings per share was $26.45.
Revenue$2.88B
Gross Profit$2.57B
Operating Income$1.38B
Pretax Income$1.54B
Net Income$1.20B
EBITDA1.61B
Earnings Per Share (EPS)26.45
Cash Flow
In the last 12 months, operating cash flow was $1.33B and capital expenditures -$246.50M, giving a free cash flow of $1.08B billion.
Operating Cash Flow$1.33B
Free Cash Flow$1.08B
Free Cash Flow per Share$24.06
Dividends & Yields
United Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield6.78%
Earnings Yield7.49%
Stock Price Statistics
Beta0.60
52-Week Price Change19.60%
50-Day Moving Average325.55
200-Day Moving Average346.51
Relative Strength Index (RSI)39.32
Average Volume (3m)522.60K
Important Dates
United Therapeutics upcoming earnings date is Apr 30, 2025, Before Open.
Last Earnings DateFeb 26, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
United Therapeutics as a current ratio of 5.25, with Debt / Equity ratio of 0.05
Current Ratio5.25
Quick Ratio5.03
Debt to Market Cap0.00
Net Debt to EBITDA-0.84
Interest Coverage Ratio32.10
Taxes
In the past 12 months, United Therapeutics has paid $343.90M in taxes.
Income Tax$343.90M
Effective Tax Rate22.35%
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 8.80, with an EV/FCF ratio of 13.47.
EV to Sales5.06
EV to EBITDA8.80
EV to Free Cash Flow13.47
EV to Operating Cash Flow10.96
Balance Sheet
United Therapeutics has $3.27B in cash and marketable securities with $300.00M in debt, giving a net cash position of -$2.97B billion.
Cash & Marketable Securities$3.27B
Total Debt$300.00M
Net Cash-$2.97B
Net Cash Per Share-$66.06
Tangible Book Value Per Share$140.09
Margins
Gross margin is 89.24%, with operating margin of 47.86%, and net profit margin of 41.53%.
Gross Margin89.24%
Operating Margin47.86%
Pretax Margin53.49%
Net Profit Margin41.53%
EBITDA Margin57.50%
EBIT Margin54.98%
Analyst Forecast
The average price target for United Therapeutics is $383.36, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$383.36
Price Target Upside36.35%
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast23.63%
EPS Growth Forecast25.66%